Increasing rates of resistance and inadequacies of current TB chemotherapeutics necessitate the need for new drugs which can potentially shorten the drug treatment, increase patient compliance and have activity against drug resistant strains including multi-drug-resistant (MDR) and extremely drug-resistant (XDR) tuberculosis